givastomig + durvalumab + chemotherapy

Givastomig + durvalumab + chemotherapy is a combination immunotherapy and cytotoxic regimen being developed for the treatment of Claudin 18.2 (CLDN18.2)-positive advanced solid tumors. The primary component, givastomig (TJ033721/ABL111), is a bispecific antibody that targets CLDN18.2 and 4-1BB (CD137). It is designed to conditionally activate T cells via the 4-1BB signaling pathway only when bound to CLDN18.2-expressing tumor cells, thereby localizing immune activation to the tumor microenvironment and minimizing systemic toxicity. Durvalumab is a monoclonal antibody that acts as a checkpoint inhibitor by binding to programmed death-ligand 1 (PD-L1), preventing it from interacting with PD-1 and B7.1, which restores anti-tumor T-cell activity. The addition of standard chemotherapy provides direct cytotoxic effects and may enhance the immune response through the release of tumor antigens. This triple combination is currently under evaluation in Phase 1 clinical trials for indications including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, pancreatic ductal adenocarcinoma, and biliary tract cancer.

Other names

TJ033721 + durvalumab + chemotherapygivastomig + durvalumab + chemotherapy